Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. Fornier MN, et al. Clin Cancer Res. 2001 Dec;7(12):3934-41. Clin Cancer Res. 2001. PMID: 11751485 Clinical Trial.
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Baselga J, et al. Among authors: sklarin nt. J Clin Oncol. 1996 Mar;14(3):737-44. doi: 10.1200/JCO.1996.14.3.737. J Clin Oncol. 1996. PMID: 8622019 Clinical Trial.
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer.
Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Chang J, Norton L, Hudis CA. Fornier MN, et al. Ann Oncol. 2011 Dec;22(12):2575-2581. doi: 10.1093/annonc/mdr018. Epub 2011 Mar 15. Ann Oncol. 2011. PMID: 21406471 Free PMC article. Clinical Trial.
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
Hudis C, Riccio L, Holmes F, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Moynahan M, Raptis G, Sklarin N, Surbone A, Uhlenhopp M, Maickel N, Yao TJ, Hellmann S, Usakewicz J, Hortobagyi G, Norton L. Hudis C, et al. Eur J Cancer. 1997 Nov;33(13):2198-202. doi: 10.1016/s0959-8049(97)00254-2. Eur J Cancer. 1997. PMID: 9470806 Clinical Trial.
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. Seidman AD, et al. J Clin Oncol. 2001 May 15;19(10):2587-95. doi: 10.1200/JCO.2001.19.10.2587. J Clin Oncol. 2001. PMID: 11352950 Clinical Trial.
36 results